A category of common medicines used to lower blood pressure, angiotensin converting enzyme inhibitors, are associated with an increased risk of lung cancer, especially if their use exceeds five years, according to a new Canadian scientific research, the largest of its kind to date.
The risk for each individual patient is relatively small, but the problem is more severe at the population level, considering, according to scientists, that a large number of people take these medicines, which are widely prescribed worldwide.
The researchers, led by the Associate Professor of Epidemiology and Oncology, Loran Azulle of McGill University of Montreal, who published the British Medical Journal (BMJ), analyzed data from nearly one million patients over 18 who were taking anti-hypertension medicines. Of these, over a period of about six years, nearly 8,000 were diagnosed with lung cancer.
It was found that those who took these drugs (“angiotensin converting enzyme inhibitors”) had an average 14% greater risk of developing lung cancer than those who took other medicines for hypertension (their inhibitors of angiotensin converting enzyme angiotensin & quot;). For those who have been using drugs for at least 10 years, the risk of cancer was increased by 31%.
People with NEA are considered effective in reducing high blood pressure. Increasing the risk for cancer seems to be due to the fact that they can increase in the lungs the level of certain chemicals such as bradykinin, which can trigger the growth of cancer cells.
Researchers called for the matter to be studied further and in the longer term. On the other hand, they pointed out that, on an individual basis, an increased risk of cancer should be weighed for each patient, in relation to the benefit for their life expectancy due to the reduction of hypertension by the drug.